Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome

Rhea-AI Summary

Therapeutic Solutions International (OTC-PINK:TSOI) announced a patent filing covering gene silencing for treating Acute Respiratory Distress Syndrome (ARDS), a significant cause of mortality. The company is conducting a Phase III trial for COVID-19 induced ARDS, seeking FDA approval to include ARDS from other causes. New data shows a 70% reduction in mortality in treated mice, indicating a survival advantage. The company aims to accelerate the development of this and other respiratory therapeutics.

Positive

• Patent filed for gene silencing in treating ARDS.
• 70% reduction in mortality observed in preclinical studies.
• FDA permission requested to expand Phase III trial.
• Commitment to advancing science in respiratory medicine.

Negative

• None.

Company Continues Accelerated Development of Candidate Pipeline and Patent Portfolio in Respiratory Medicine Space as Phase III Trial Proceeds

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International announced today data and filing of a patent covering the use of “gene silencing” in treatment of Acute Respiratory Distress Syndrome (ARDS), a leading cause of death in emergency rooms.

The Company currently is running a Phase III trial treating COVID-19 induced ARDS but has requested permission from the FDA to expand to ARDS caused by other precipitating factors.

The new data demonstrates feasibility of selectively silencing genes in the lung associated with mortality caused by ARDS, as well as a potent survival advantage in treated versus untreated mice. An approximately 70% reduction in mortality was observed in mice receiving siRNA specifically towards the target genes as compared to mice receiving scrambled siRNA in a TLR4 agonist induced model of ARDS.

The Company plans to continue development of this approach, which is attempted to synergize with the current regenerative medicine programs currently underway.

“We are committed to making a significant impact in the lives of patients with ARDS. As part of that commitment, we need to constantly push the limits of medicine and science,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “Having previously demonstrated our ability to initiate and run clinical trials, as well as obtain Emergency IND approval, we are confident that we are in the position to accelerate this and other therapeutics in the area of respiratory medicine for which no curative therapeutic approaches exist.”

“The value of a biotechnology company is in its programs and intellectual property. As our ongoing Phase III continues, our team is brilliantly leveraging this waiting period to continually advance our science. This is what patients and investors count on use to do,” said Timothy Dixon, President and CEO of the Company.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005264/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What is the recent patent filed by Therapeutic Solutions International?

Therapeutic Solutions International filed a patent covering gene silencing for treating Acute Respiratory Distress Syndrome (ARDS).

What are the results of the Phase III trial by TSOI for ARDS?

The Phase III trial focuses on COVID-19 induced ARDS, and the company is seeking FDA approval to include other causes of ARDS.

How effective is the gene silencing treatment for ARDS according to the recent data?

Recent data shows a 70% reduction in mortality in treated mice, indicating a potent survival advantage.

What are TSOI's future plans regarding their respiratory medicine initiatives?

The company plans to continue developing gene silencing approaches alongside ongoing regenerative medicine programs.